Corosolic Acid lowers blood sugar significantly
Researchers from the Department of Diabetes and Clinical Nutrition at Kyoto University gave 31 people either 10mg Corosolic Acid or inactive placebo a number of times, 5 minutes before an oral glucose tolerance test consisting of drinking 75-g of sugar in water in a cross-over design. The test subjects had diabetes, or impaired glucose tolerance, impaired fasting glucose, and 4 had normal sugar activity. The Corosolic Acid lowered blood glucose within 60 minutes and reached statistical significance by 90 minutes. The study is published in the August 2006 issue of the Irish medical journal Diabetes Research and Clinical Practice.
Corosolic Acid significantly improves blood sugar in type II diabetics
In this study type II diabetics who were not using insulin were supplemented with Corosolic Acid for two weeks. The supplement significantly improved blood sugar levels by 20% to 30%. The study is published in the July 2003 issue of the Irish publication Journal of Ethnopharmacology.
Cinnamon improves glucose and lipids of people with type 2 diabetes
In this study 60 people with type 2 diabetes (30 mne/30 women) between the age of 46 to 58 were given various dosages of Cinnamon or placebo for 40 days. Cinnamon reduced fasting blood glucose by 18-29%, triglycerides by 23-30%, LDL-cholesterol by 7-27%, and total cholesterol by 12-26%. There were no significant changes in the placebo group. Using Cinnamon in patients with type 2 diabetes will reduce risk factors associated with diabetes and cardiovascular disease. The study is published in the December 2003 issue of the journal Diabetes Care.
Aqueous Extract of Cinnamon reduces fasting blood sugar in diabetics
on oral drugs
In this study 79 patients with Type 2 diabetes who were taking medication other than insulin or on a strict diet were given an Aqueous Extract of Cinnamon corresponding to 3 grams of Cinnamon a day for 4 months or an inactive placebo. The Cinnamon Extract caused the fasting blood glucose to drop by 10.3% on average, far more than placebo (3.4%). The study is published in the May 2006 issue of the European Journal of Clinical Investigation.